Philips CEO Says They Will Hit 4% to 6% Growth Target

The transcript discusses Phillips' business performance, highlighting growth in personal health and emerging markets, particularly China. Challenges in Europe and North America are noted, with a focus on innovation and strategic acquisitions to drive growth. The impact of FX headwinds and tariffs on pricing is addressed, alongside Phillips' healthcare strategy and alignment with China's Health Care 2030 plan. The discussion also touches on trade relations between the US and China, emphasizing Phillips' neutral stance and global presence.

What role does innovation play in the company's pricing strategy?

What is the significance of the Health Care 2030 strategy in China?

How does the company view the geopolitical situation regarding trade deals?